Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Live tumor fragment platform predicts immunotherapy response — translational tool

January 05, 2026

Researchers unveiled a live tumor fragment platform that preserves tumor architecture and immune components ex vivo to test immunotherapy responses across multiple agents. The system enables...

Liquid biopsy collaboration maps MASH biology — Hepta leads effort

January 05, 2026

Hepta announced a collaboration to map the biology of metabolic dysfunction‑associated steatohepatitis (MASH) using a novel liquid biopsy platform designed to capture multiomic signals from blood....

Serum biomarkers track MIS‑C severity and recovery: Pediatric Research

January 05, 2026

A Pediatric Research study identified serum immune biomarkers that correlate with severity and clinical recovery in multisystem inflammatory syndrome in children (MIS‑C). Investigators measured...

High‑CD14 urothelial cells drive neutrophil‑rich microenvironment after radiation

January 05, 2026

A study by Chiang et al. reported that urothelial cancers with high CD14 expression sculpt a neutrophil‑rich tumor microenvironment following radiation, which can blunt antitumor immunity and...

Setrusumab misses fracture endpoints – Ultragenyx, Mereo to cut costs

January 05, 2026

Ultragenyx and Mereo announced that setrusumab failed to meet primary fracture endpoints in two late-stage trials, prompting an immediate reassessment of operations and planned expense reductions....

St. Jude unveils method to detect base-editor off-targets – safety tool released

January 05, 2026

St. Jude Children's Research Hospital published a new method to more sensitively identify small off-target genome edits from base editors, enabling clearer safety assessments for precision genome...

AAV9 optimization advances for SMARD1 – efficiency and safety signals reported

January 05, 2026

Researchers reported optimized AAV9-based gene therapy strategies for SMARD1 (spinal muscular atrophy with respiratory distress type 1) that improve delivery and therapeutic indices in preclinical...

Tiny peptide reverses colorectal immune evasion – lipid signature fuels progression

January 05, 2026

Two independent studies revealed actionable mechanisms driving colorectal cancer immune escape and progression. A Cell Research report described an engineered 11–amino–acid peptide derived from...

Ex vivo tumor fragments and single-cell maps... new tools to test immunotherapies

January 05, 2026

Teams reported two complementary advances for evaluating cancer therapies ex vivo and in situ. A live tumor fragment platform enables functional testing of immunotherapies on intact tumor...

High‑CD14 urothelial cells recruit neutrophils after radiation – pro‑metastatic niche

January 05, 2026

Chiang et al. report that urothelial cancer cells with elevated CD14 expression reshape the tumor microenvironment into a neutrophil‑rich state following radiation. The study links tumor-intrinsic...

Psilocybin-assisted therapy shows early signal in binge‑eating pilot – small study

January 05, 2026

A pilot study led by Dr. Dallery tested psilocybin‑assisted therapy in patients with binge eating disorder (BED) and reported reductions in binge episodes and improvements in eating-related...

Serum biomarkers map MIS‑C severity and recovery – pediatric immune signatures

January 05, 2026

Wolff and Koutroulis published a Pediatric Research study identifying serum immune biomarkers that track severity and recovery in Multisystem Inflammatory Syndrome in Children (MIS‑C). The...

LowLoad‑qPCR spots low‑load bacteremia – diagnostic sensitivity improved

January 05, 2026

Researchers described LowLoad‑qPCR, a refined quantitative PCR protocol that improves detection of low‑load bacteremia—bloodstream infections with low bacterial counts that commonly evade standard...

CDH17+, tight‑junction tumor cells identified as liver‑metastasis instigators

January 05, 2026

A Nature Communications study identified a discrete subset of tumor cells—tight junction‑high and CDH17‑positive—that act as primary instigators of colorectal cancer liver metastases. The authors...

Ultragenyx, Mereo: setrusumab misses Phase III – expense cuts planned

January 05, 2026

Ultragenyx and partner Mereo reported that setrusumab failed to meet primary endpoints in two Phase III trials for brittle bone disease (osteogenesis imperfecta), prompting immediate operational...

St. Jude: new method spots off-targets from base editors

January 05, 2026

St. Jude Children’s Research Hospital published a new method intended to improve detection of small off-target edits generated by base editors, the team said. The approach provides a...

BEAVER trial: binimetinib–encorafenib show responses in non‑V600E BRAF tumors

January 05, 2026

The Phase II BEAVER trial reported tumor responses to the MEK inhibitor binimetinib combined with the BRAF inhibitor encorafenib in patients with advanced solid tumors harboring non‑V600E BRAF...

Autologous CD133+ cells: early trial suggests repair for Asherman

January 05, 2026

A Phase 1/2 clinical trial tested autologous CD133+ bone marrow–derived stem cells for Asherman syndrome and reported preliminary signals of endometrial repair, investigators said. The single-arm...

SMLM imaging: extracellular vesicle DNA tracked inside recipient cells

January 05, 2026

Researchers deployed single-molecule localization microscopy (SMLM) to visualize extracellular vesicle (EV) DNA dynamics inside recipient cells, reporting direct imaging of EV-borne nucleic acids...

Acute exercise reshapes immune cell proteome – Nature Communications study

January 05, 2026

A new Nature Communications report shows that acute exercise triggers rapid and widespread remodeling of the proteomic architecture in human immune cells, researchers Walzik, Joisten and Metcalfe...